Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Vastra Gotaland Region
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06419946CT.gov Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma | — | Recruiting | — | — | — |
NCT06283927CT.gov The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · IDH-Wildtype Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lomustine (this asset) | Vastra Gotaland Region | P3 | B · 56 |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | National Cancer Institute (NCI) | P2 | B |
| Ipilimumab | Neonc Technologies, Inc. | P2 | B |
| Nivolumab | Neonc Technologies, Inc. | P2 | B |
| Pembrolizumab | Mayo Clinic | P2 | B |
| Cerebraca Wafer | Everfront Biotech Co., Ltd. | P2/3 | B |
| Tiragolumab | National Cancer Institute (NCI) | P2 | CCC |
| gi-102 | Mayo Clinic | P2 | CCC |
| Adriamycin | Northwestern University | P2 | CCC |
+36 more in the IDH-Wildtype Glioblastoma cohort
Other indications for Lomustine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Central Nervous System Neoplasm | — | P3 | BB · 68 |
| Glioblastoma | — | P3 | BB · 67 |
| Diffuse Large B-Cell Lymphoma | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerNational Cancer Institute (NCI)B
- IpilimumabNeonc Technologies, Inc.B
- NivolumabNeonc Technologies, Inc.B
- PembrolizumabMayo ClinicB
- Cerebraca WaferEverfront Biotech Co., Ltd.B
Citation
Floatz Terminal. Lomustine in IDH-Wildtype Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lomustine-idh-wildtype-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →